The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies announced it will present multiple encore presentations supporting its TSHA-102 clinical program for Rett syndrome at the 55th Annual Meeting of the Child Neurology Society.
The company is aiming to advance the development of TSHA-102 as a potential gene therapy for patients with Rett syndrome. These presentations are intended to provide updates and reinforce clinical data for the investigational program.
View post on X Loading...